MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$3,962K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accrued liabilities
Accounts payable
Accrued compensation
Others
Negative Cash Flow Breakdown
Purchases of short-term investme...
Other current assets
Deferred revenues
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-20,186
-16,633
-237,101
-174,442
Depreciation
343
151
1,496
1,056
Loss on disposal of property and equipment
-
-
-57
-83
Stock-based compensation expense
893
12,213
43,419
19,024
Non-cash operating lease costs
754
841
1,570
1,027
Collaboration receivable
-
15,000
-
-
Amortization of premiums and discounts on short-term investments, net
250
-
1,487
2,405
Prepaid assets
1,928
1,043
2,551
24,205
Other current assets
6,232
-1,208
-
-
Accounts payable
2,706
-3,591
2,687
5,782
Accrued liabilities
6,329
-1,995
-
-
Accrued expenses and other liabilities
-
-
23,711
35,140
Accrued compensation
1,871
-15,838
-
-
Operating right-of-use assets and lease liabilities, net
-
-
-715
-2,031
Lease liabilities
-997
890
-
-
Deferred revenues
-3,004
-4,635
-859
-2,339
Other long-term liabilities
775
-574
-
-
Net cash used in operating activities
-3,926
-31,143
-169,773
-156,173
Proceeds from maturities of marketable securities
-
-
223,618
269,564
Purchases of short-term investments
191,551
-
9,998
853,603
Purchases of property and equipment
36
2,098
5,511
712
Tenant improvements capitalized to right-of-use assets
-
-
891
3,175
Net cash used in investing activities
-191,587
-2,098
207,218
-587,926
Proceeds from issuance of common stock in public offerings, net of issuance costs
-
-
-538
837,420
Proceeds from issuance of common stock in private placements, net of issuance costs and allocation to deferred revenues (note 5)
-
-
0
0
Proceeds from issuance of pre-funded warrants in a private placement, net of issuance costs
-
-
0
0
Proceeds from the issuance of common stock under employee incentive equity plans
-
-
7,861
12,946
Payments for taxes related to net share settlement of equity awards
-
-
12,409
-
Net transfers from former parent
0
301,505
-
-
Net cash provided by financing activities
0
301,505
-5,086
850,366
Effect of exchange rate on cash, cash equivalents and restricted cash
-
-
-1
-16
Net increase in cash, cash equivalents, and restricted cash
-195,513
268,264
32,358
106,251
Cash, cash equivalents and restricted cash, at beginning of period
268,264
0
352,956
222,663
Cash, cash equivalents and restricted cash, at end of period
72,751
-
-
-
Cash and cash equivalents
72,334
-
-
-
Restricted cash included in current assets
311
-
-
-
Restricted cash included in non-current assets
106
-
-
-
Total cash, cash equivalents and restricted cash
72,751
268,264
385,314
352,956
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase in
cash, cash...
-$195,513K
(-913.21%↓ Y/Y)
something is missing
$15,000K
Accrued liabilities
$6,329K
Accounts payable
$2,706K
(157.94%↑ Y/Y)
Accrued compensation
$1,871K
(-87.34%↓ Y/Y)
Stock-based compensation
expense
$893K
(-97.48%↓ Y/Y)
Other long-term
liabilities
$775K
Non-cash operating lease
costs
$754K
(-54.16%↓ Y/Y)
Depreciation
$343K
(-78.55%↓ Y/Y)
Net cash used in
investing activities
-$191,587K
(-155.91%↓ Y/Y)
Net cash used in
operating activities
-$3,926K
(98.79%↑ Y/Y)
Canceled cashflow
$28,671K
Purchases of short-term
investments
$191,551K
(-21.26%↓ Y/Y)
Purchases of property and
equipment
$36K
(-99.49%↓ Y/Y)
Net loss
-$20,186K
(92.61%↑ Y/Y)
Other current assets
$6,232K
Deferred revenues
-$3,004K
(44.58%↑ Y/Y)
Prepaid assets
$1,928K
(-98.34%↓ Y/Y)
Lease liabilities
-$997K
(48.05%↑ Y/Y)
Amortization of premiums and
discounts on short-term...
$250K
(-97.10%↓ Y/Y)
Buy us a coffee
Atrium Therapeutics, Inc. (RNA)
Atrium Therapeutics, Inc. (RNA)